Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Bleb Vascularity Post-Trabeculectomy
NCT00815594Phase 4Unknown
- Sponsor
- Capital Medical University
- Start
- Dec 2008
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in Conjunctival scarring, sponsored by Capital Medical University. Primary endpoint: Bleb vascularity change at 1 month. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
Conjunctival scarring
Beyond the preview
Go deeper on NCT00815594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00815594.